TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2023-03-10T11:01:16+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|Comments Off on TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]